Investing.com – Swiss-based Roche Holding's bumper offer to acquire Spark Therapeutics on Monday propped up the healthcare sector and fueled speculation on Wall Street that...
By John Miller ZURICH (Reuters) - Roche is buying U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion after developments in this area convinced the Swiss...
Jefferies healthcare strategist Jared Holtz is a short-term biotech bear saying that profit-taking "makes sense" through this earnings season considering the sector's...
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that it will file regulatory applications seeking approval of valoctocogene roxaparvovec, its gene therapy, for severe...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Sell|
|Technical Indicators||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Strong Sell|
|Summary||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Strong Sell|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Upside Gap Three Methods||15||Current|
|Bullish doji Star||1H||Current|
|Three Outside Down||5H||Current|
|Engulfing Bearish||5H||1||Jul 19, 2019 07:00AM|
|Doji Star Bearish||5H||2||Jul 18, 2019 11:00AM|
|Bullish Engulfing||1H||2||Jul 19, 2019 01:00PM|
BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.Read More
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.